Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

Michael B. Atkins; Ragini Reiney Kudchadkar; Mario Sznol; David F. McDermott; Michal Lotem; Jacob Schachter; Jedd D. Wolchok; Walter John Urba; Timothy Kuzel; Lynn Mara Schuchter; Craig L. Slingluff; Marc S. Ernstoff; Joseph W. Fay; Philip Adam Friedlander; Thomas Gajewski; Hassane M. Zarour; Rinat Rotem-Yehudar; Jeffrey Alan Sosman

Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

Michael B. Atkins
, Ragini Reiney Kudchadkar
, Mario Sznol
, David F. McDermott
, Michal Lotem
, Jacob Schachter
, Jedd D. Wolchok
, Walter John Urba
, Timothy Kuzel
, Lynn Mara Schuchter
, Craig L. Slingluff
, Marc S. Ernstoff
, Joseph W. Fay
, Philip Adam Friedlander
, Thomas Gajewski
, Hassane M. Zarour
, Rinat Rotem-Yehudar
, Jeffrey Alan Sosman

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
State	Published - Jan 31 2017

Disciplines

Medicine and Health Sciences
Pathology

Cite this

Atkins, M. B., Kudchadkar, R. R., Sznol, M., McDermott, D. F., Lotem, M., Schachter, J., Wolchok, J. D., Urba, W. J., Kuzel, T., Schuchter, L. M., Slingluff, C. L., Ernstoff, M. S., Fay, J. W., Friedlander, P. A., Gajewski, T., Zarour, H. M., Rotem-Yehudar, R., & Sosman, J. A. (2017). Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. Journal of Clinical Oncology.

@article{0e7e39d281b246b0bed880001ff5de4f,

title = "Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.",

author = "Atkins, \{Michael B.\} and Kudchadkar, \{Ragini Reiney\} and Mario Sznol and McDermott, \{David F.\} and Michal Lotem and Jacob Schachter and Wolchok, \{Jedd D.\} and Urba, \{Walter John\} and Timothy Kuzel and Schuchter, \{Lynn Mara\} and Slingluff, \{Craig L.\} and Ernstoff, \{Marc S.\} and Fay, \{Joseph W.\} and Friedlander, \{Philip Adam\} and Thomas Gajewski and Zarour, \{Hassane M.\} and Rinat Rotem-Yehudar and Sosman, \{Jeffrey Alan\}",

note = "Background: Pidilizumab (CT-011), a humanized anti PD-1 IgG1k, was studied in two Phase 2 studies in aggressive and indolent lymphomas showing clinical activity correlated with PD-1/PD-L1+ lymphocytes. Thus, we initiated a Phase 2 multicenter, randomized, open-label, study to evaluate the safety and efficacy of pidilizumab in patients (pts) with metastatic melanoma (MM).",

year = "2017",

month = jan,

day = "31",

language = "American English",

journal = "Journal of Clinical Oncology",

}

Atkins, MB, Kudchadkar, RR, Sznol, M, McDermott, DF, Lotem, M, Schachter, J, Wolchok, JD, Urba, WJ, Kuzel, T, Schuchter, LM, Slingluff, CL, Ernstoff, MS, Fay, JW, Friedlander, PA, Gajewski, T, Zarour, HM, Rotem-Yehudar, R & Sosman, JA 2017, 'Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.', Journal of Clinical Oncology.

TY - JOUR

T1 - Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

AU - Atkins, Michael B.

AU - Kudchadkar, Ragini Reiney

AU - Sznol, Mario

AU - McDermott, David F.

AU - Lotem, Michal

AU - Schachter, Jacob

AU - Wolchok, Jedd D.

AU - Urba, Walter John

AU - Kuzel, Timothy

AU - Schuchter, Lynn Mara

AU - Slingluff, Craig L.

AU - Ernstoff, Marc S.

AU - Fay, Joseph W.

AU - Friedlander, Philip Adam

AU - Gajewski, Thomas

AU - Zarour, Hassane M.

AU - Rotem-Yehudar, Rinat

AU - Sosman, Jeffrey Alan

N1 - Background: Pidilizumab (CT-011), a humanized anti PD-1 IgG1k, was studied in two Phase 2 studies in aggressive and indolent lymphomas showing clinical activity correlated with PD-1/PD-L1+ lymphocytes. Thus, we initiated a Phase 2 multicenter, randomized, open-label, study to evaluate the safety and efficacy of pidilizumab in patients (pts) with metastatic melanoma (MM).

PY - 2017/1/31

Y1 - 2017/1/31

UR - http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.9001

M3 - Article

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

Disciplines

Other files and links

Cite this